D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target

Benzinga · 11/25/2025 12:58
D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price target.